Coherus BioSciences (NASDAQ:CHRS) Upgraded at StockNews.com

StockNews.com upgraded shares of Coherus BioSciences (NASDAQ:CHRS) from a hold rating to a buy rating in a research note released on Friday.

A number of other research analysts also recently weighed in on the stock. HC Wainwright restated a buy rating and set a $12.00 price target on shares of Coherus BioSciences in a report on Monday, September 16th. UBS Group lowered Coherus BioSciences from a buy rating to a neutral rating and cut their target price for the company from $4.00 to $1.50 in a report on Friday, August 16th. Finally, Robert W. Baird decreased their price target on Coherus BioSciences from $9.00 to $8.00 and set an outperform rating for the company in a research note on Monday, July 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $7.10.

Coherus BioSciences Price Performance

Shares of NASDAQ CHRS opened at $0.99 on Friday. Coherus BioSciences has a one year low of $0.94 and a one year high of $3.98. The business’s 50-day moving average price is $1.22 and its two-hundred day moving average price is $1.65. The company has a market capitalization of $113.60 million, a P/E ratio of -1.27 and a beta of 0.65.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.10. The firm had revenue of $64.98 million during the quarter, compared to the consensus estimate of $57.08 million. On average, equities analysts anticipate that Coherus BioSciences will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Coherus BioSciences

Hedge funds have recently bought and sold shares of the company. Nomura Holdings Inc. lifted its position in shares of Coherus BioSciences by 225.1% during the 4th quarter. Nomura Holdings Inc. now owns 68,300 shares of the biotechnology company’s stock worth $227,000 after purchasing an additional 47,290 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in shares of Coherus BioSciences by 43.4% during the first quarter. Los Angeles Capital Management LLC now owns 196,210 shares of the biotechnology company’s stock worth $469,000 after buying an additional 59,390 shares during the last quarter. RFG Advisory LLC bought a new stake in shares of Coherus BioSciences in the first quarter valued at approximately $142,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Coherus BioSciences by 66.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 21,426 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 8,546 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Coherus BioSciences during the first quarter worth $108,000. 72.82% of the stock is currently owned by institutional investors.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.